SOLICITATION NOTICE
B -- Chromatin Isolation & Processing
- Notice Date
- 4/27/2011
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110058-MW
- Archive Date
- 5/26/2011
- Point of Contact
- Melissa R. Ward, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
wardmr@mail.nih.gov, cr214i@nih.gov
(wardmr@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6072, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG), plans to procure on a sole source basis with Active Motif Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008 to perform chromatin isolation and processing from formaldehyde-fixed PBMC cell pellets as well as chromatin immunoprecipitation (ChIP) from isolated chromatin using H3K27me3 and H3K4me2 specific antibodies to produce ChIP DNAs. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541690 and the business size standard in $7.0M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for three months from date of award. CDKN2A is a major susceptibility for familial melanoma, but its incomplete penetrance suggests that other factors may modify the effect of this gene in melanoma-prone families. The NCI hypothesizes that the CDKN2A carrier mutation state may be an important factor influencing epigenetic processes in predisposed individuals, and that specific histone patterns in the genome may modify melanoma risk in melanoma-prone families segregating CDKN2A germline mutations. The objectives of this procurement are to determine whether changes in constitutional histone 3 lysine 27 tri-methylated (H3K27me3) and histone 3 lysine 4 di-methylated (H3K4me2) histone methylation signatures are associated with germline CDKN2A mutation status. This insight may have the potential to identify melanoma-related histone patterns in CDKN2A mutation carriers that could be important for cancer risk and progression. The contractor shall isolate chromatin from each of 10 formaldehyde-fixed EBV-PBMC cell pellets provided by NCI, fragment chromatin using sonication and carryout nanodrop quantitation and agarose gel electrophoresis analyses, prepare specific H3K27me3 and H3K4me2 chromatin DNAs, and carry out all necessary quality control checks. The ChIP method has emerged as a very powerful tool to study in vivo histone-DNA interactions. It has been applied to the dynamics of chromatin structure, regulation by transcription factors and identification of changes in histone marks throughout the genome. Active Motif is a high-throughput service provider for preparation and analysis of chromatin immunoprecipitation (ChIP) DNAs. For this procurement, Active Motif can provide a complete end-to-end service package for ChIP DNA preparation from fixed cell pellets including all QC checks to ensure successful output for sequence (ChIP-Seq) analysis. Active motif is considered international leading providers in commercial reagents and kits for ChIP together with the provision of in-house chromatin preparation and ChIP DNA analyses services. Active Motif is the best and only known service provider known that can prepare successful ChIP DNAs from fixed cell pellets for this project. This will provide NCI with the necessary high-quality preparation of chromatin and ChIP DNAs from fixed PBMC cell pellets, and sequently allow the genome-wide mapping of histone marks using sequence analysis at our NCI core facility. In addition, Active Motif's ChIP protocols offer higher sensitivity and lower non-specific background compared with other ChIP methods in general use today and thus their output or ChIP DNAs result in more informative ChIP-Seq data including the detection of sites containing much lower levels of histone binding. Active Motif also provides optimized QC steps throughout the procedure to monitor chromatin preparation as well as determine if results are due to ChIP or the antibody, and if the ChIP assay has errors. This will ensure the successful preparation of all the ChIP DNAs from each of the 10 cell pellets (from subjects in the 873 melanoma-prone family), which will ensure that the results produced under this procurement will be: 1) Successful and comparable across the different family members and between the two different ChIP analyses (H3K27me3 and H3K4me2); and 2) Will be successfully completed in time for subsequent sequence (ChIP-Seq) analysis and data output by the NCI Sequencing Core Facility, which is vital to the success of this project Thus, to our knowledge Active Motif is the only company that provides a start-to-finish ChIP-Seq services (including ChIP experimental design and consultation, chromatin preparation, antibody performance and validation, performance of ChIP assays with post-ChIP QC, sequencing, and comprehensive data analysis). This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on May 11, 2011. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Ward, Contract Specialist, at wardmr@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110058-MW on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110058-MW/listing.html)
- Record
- SN02435067-W 20110429/110427235119-2de2f49a10489bed7015c3426864416b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |